Phenethyl Isothiocyanate and Cisplatin Co-Encapsulated in a Liposomal Nanoparticle for Treatment of Non-Small Cell Lung Cancer
Phenethyl Isothiocyanate and Cisplatin Co-Encapsulated in a Liposomal Nanoparticle for Treatment of Non-Small Cell Lung Cancer
复制标题
DOI：
10.3390/molecules24040801
复制
发表时间：
2019-02-02
期刊：
影响因子：
4.6
通讯作者：
Di Pasqua, Anthony J.
中科院分区：
文献类型：
--
作者：
Sun, Mengwei;Shi, Yi;Di Pasqua, Anthony J.
在美国，肺癌是癌症相关死亡的主要原因，并且大约85%的所有肺癌被分类为非小细胞肺癌（NSCLC），其极难治疗并且其存活率低。经过几十年的临床试验，最有效的治疗方法仍然是实施第一代铂类抗癌药顺铂（CDDP）与其他药物联合使用。我们以前证明，天然化合物苯乙基异硫氰酸酯（PEITC）可用于敏化NSCLC细胞CDDP。此外，PEITC和CDDP在脂质体中的共包封增强了它们对NSCLC细胞的毒性。我们在此优化了脂质体-PEITC-CDDP，证明了PEITC和CDDP从纳米颗粒中的释放，并表明脂质体-PEITC-CDDP对A549和H596人NSCLC细胞系的毒性比对WI-38和BEAS-2B人正常肺细胞系的毒性大得多。因此，我们已经制备了一种有效的疗法，其对癌细胞系的毒性显著高于正常细胞系。
Lung cancer is the leading cause of cancer-related death in the Unites States, and approximately 85% of all lung cancers are classified as non-small cell lung cancer (NSCLC), which is extremely difficult to treat and its survival rate is low. After decades of clinical trials, the most effective treatments are still those that implement the first-generation platinum anticancer agent cisplatin (CDDP) in combination with other drugs. We previously demonstrated that the naturally-occurring compound phenethyl isothiocyanate (PEITC) can be used to sensitize NSCLC cells to CDDP. Furthermore, co-encapsulation of PEITC and CDDP in liposomes enhances their toxicity toward NSCLC cells. We here optimize liposomal-PEITC-CDDP, demonstrate the release of PEITC and CDDP from the nanoparticle, and show that liposomal-PEITC-CDDP is much more toxic toward both A549 and H596 human NSCLC cell lines than toward WI-38 and BEAS-2B human normal lung cell lines. Thus, we have prepared an efficacious therapy that has significantly higher toxicity toward cancer cell lines than normal cell lines.